What is the recommended rituximab dosing schedule, pre‑infusion screening, and monitoring for a patient with minimal change disease who is steroid‑dependent, frequently relapsing, or steroid‑resistant after failure or toxicity of cyclophosphamide, calcineurin inhibitors, and mycophenolate?

Rituximab for Minimal Change Disease: Dosing, Screening, and Monitoring

Recommended Rituximab Dosing Schedule

For adults with steroid-dependent or frequently relapsing minimal change disease who have failed or cannot tolerate cyclophosphamide, calcineurin inhibitors, and mycophenolate, rituximab should be administered at 375 mg/m² weekly for 4 doses OR 1000 mg given as two doses separated by 2 weeks. 1, 2, 3

Dosing Options Based on Evidence:

• Standard lymphoma protocol: 375 mg/m² intravenously weekly for 4 consecutive weeks 1, 3
• Rheumatology protocol: 1000 mg intravenously on day 1 and day 15 (two doses separated by 2 weeks) 1, 4
• Both regimens appear clinically equivalent in achieving B-cell depletion and inducing remission 1, 4

Re-dosing Strategy:

• Maintenance dosing: Consider repeat dosing at 6 months if B-cell reconstitution occurs (CD19+ >100 cells/µL) or if relapse occurs 5, 6
• Single-dose rituximab (375 mg/m²) has shown efficacy in some pediatric studies but is less established in adults 3
• Most adult patients require 2-4 doses for optimal B-cell depletion and sustained remission 4, 7, 8

---

Pre-Infusion Screening Requirements

Mandatory Infectious Disease Screening:

• Hepatitis B screening: Test for HBsAg, anti-HBc, and anti-HBs before initiating rituximab to prevent viral reactivation 5, 2
• Hepatitis C screening: Recommended in high-risk populations 2
• HIV testing: Should be performed in appropriate clinical contexts 2
• Tuberculosis screening: PPD or interferon-gamma release assay (IGRA) 2

Baseline Laboratory Assessment:

• Complete blood count with differential: Establish baseline white blood cell and lymphocyte counts 2
• Immunoglobulin levels (IgG, IgA, IgM): Baseline measurement essential as hypogammaglobulinemia develops in approximately 17% of patients after median 5.4 years of treatment 5, 2
• Renal function and proteinuria: Baseline serum creatinine, eGFR, and urine protein-to-creatinine ratio 2
• Serum albumin: Important for assessing thromboembolism risk and treatment response 2

Vaccination Status:

• Complete all non-live vaccines BEFORE starting rituximab when possible, as vaccine responses are impaired during B-cell depletion 5
• Avoid live vaccines during treatment and while B-cells remain depleted 5
• Consider pneumococcal, influenza, and hepatitis B vaccines if not previously administered 5

---

Monitoring During and After Treatment

Immediate Post-Infusion Monitoring:

• Infusion reactions: Monitor vital signs during and for 1-2 hours after each infusion 2
• Premedication with acetaminophen and antihistamines reduces infusion reaction risk 2

B-Cell Depletion Monitoring:

• CD19+ or CD20+ B-cell counts: Check at 1-3 months after rituximab to confirm B-cell depletion (target <0.5% or <5 cells/µL) 3, 4, 6
• B-cell reconstitution typically occurs 1-6 months after treatment (mean 2.92 months in one study) 3
• Relapse risk increases when CD19+ counts exceed 100 cells/µL 6
• Important caveat: B-cell depletion alone does not predict clinical response; some patients remain in remission despite B-cell recovery 4, 6

Clinical Response Assessment:

• Do NOT expect immediate proteinuria reduction: Rituximab may take 3-6 months to show clinical benefit 2
• Monitor at 3-month intervals: Urine protein-to-creatinine ratio and serum albumin 2, 8
• Complete remission definition: Urine protein <0.3 g/day or urine protein-to-creatinine ratio <300 mg/g 1
• Relapse frequency: Calculate as ratio of relapse episodes to follow-up years; expect significant reduction from baseline (e.g., from 1.71 to 0.04 relapses/year) 8

Long-Term Safety Monitoring:

• Immunoglobulin levels every 3-6 months: Monitor for hypogammaglobulinemia (IgG <3 g/L) 5, 2
  • If IgG falls below 3 g/L with recurrent severe infections, consider immunoglobulin replacement therapy 5
• Infection surveillance: Serious infections requiring hospitalization occur in 13% of patients on long-term rituximab 5
• Pneumocystis jirovecii pneumonia (PCP) prophylaxis: Strongly recommended with trimethoprim-sulfamethoxazole during treatment and for 6-12 months after last dose 2

Supportive Care Requirements:

• Renin-angiotensin-aldosterone system (RAS) blockade: Continue ACE inhibitor or ARB for proteinuria control 2
• Blood pressure target: Maintain <130/80 mmHg 2
• Anticoagulation: Strongly consider prophylactic anticoagulation when serum albumin <20-25 g/L due to high thromboembolism risk 2
• Glucocorticoid continuation: Continue glucocorticoids for 2 weeks after initiating rituximab, then taper gradually 1

---

Expected Clinical Outcomes

Efficacy Data:

• Complete remission rates: 70-81% of adult patients achieve complete remission 4, 7, 8
• Steroid-free survival: Median 16.7-25 months after rituximab treatment 8, 6
• Immunosuppression cessation: 70.4% of patients achieve complete cessation of corticosteroids and other immunosuppressants within 3 months 8
• Relapse reduction: Mean relapse frequency decreases from 2.60 to 0.4 episodes per year 6

Risk Factors for Relapse:

• Low serum albumin before rituximab treatment predicts higher relapse risk 8
• High CD56+CD16+ natural killer cell count after rituximab independently predicts relapse within 2 years 8
• B-cell reconstitution: 71% of relapses occur when CD19+ counts exceed 100 cells/µL 6

---

Common Pitfalls and How to Avoid Them

Pitfall 1: Expecting Immediate Response

• Avoid: Do not declare treatment failure if proteinuria persists at 1-2 months 2
• Solution: Wait at least 3-6 months before assessing clinical response 2, 8

Pitfall 2: Inadequate Infection Prophylaxis

• Avoid: Failing to prescribe PCP prophylaxis leads to preventable serious infections 2
• Solution: Prescribe trimethoprim-sulfamethoxazole routinely during and for 6-12 months after rituximab 2

Pitfall 3: Premature Glucocorticoid Withdrawal

• Avoid: Stopping steroids immediately after rituximab increases relapse risk 1
• Solution: Continue glucocorticoids for at least 2 weeks after rituximab initiation, then taper slowly 1

Pitfall 4: Ignoring Immunoglobulin Monitoring

• Avoid: Hypogammaglobulinemia develops insidiously and increases infection risk 5
• Solution: Check immunoglobulin levels every 3-6 months throughout treatment 5, 2

Pitfall 5: Relying Solely on B-Cell Counts

• Avoid: B-cell depletion does not guarantee sustained remission; some patients relapse despite depletion, while others remain in remission after B-cell recovery 4, 6
• Solution: Use B-cell counts as one parameter among multiple clinical indicators (proteinuria, albumin, relapse frequency) 2, 6